- Home
- REED vs CURX Comparison
REED vs CURX Comparison
Compare REED & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REED | CURX |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.8M |
| IPO Year | 2009 | 2024 |
Fundamental Metrics
Financial Performance| Metric | REED | CURX |
|---|---|---|
| Price | $0.77 | $5.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 20.3K |
| Earning Date | 11-10-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,065,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $0.21 |
| 52 Week High | $5.97 | $13.80 |
Technical Indicators
Market Signals| Indicator | REED | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 57.78 | 59.08 |
| Support Level | $0.72 | $5.24 |
| Resistance Level | $1.04 | $6.00 |
| Average True Range (ATR) | 0.17 | 0.44 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 54.63 | 78.57 |
Price Performance
Historical ComparisonAbout REED Reed's Inc.
Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.